Chemokines in onchocerciasis patients after a single dose of ivermectin

Clinical and Experimental Immunology

Volumn 142, Issue 2, 2005, Pages 318-326

  Fendt, J ^a   Hamm, D M ^a   Banla, M ^b   Schulz Key, H ^a   Wolf, H ^a   Helling Giese, G ^a   Heuschkel, C ^a   Soboslay, P T ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITÉ DE LOMÉ   (Togo)

Author keywords

Chemokines; Ivermectin treatment; Onchocerca volvulus infection

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; CUTANEOUS T CELL ATTRACTING CHEMOKINE; IVERMECTIN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLACEBO; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EUROPE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MICROFILARIA; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHOOL CHILD; SCORING SYSTEM; SERUM; SIDE EFFECT; SINGLE DRUG DOSE; SKIN; TH2 CELL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANIMALS; ANTINEMATODAL AGENTS; CHEMOKINES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IVERMECTIN; MALE; MIDDLE AGED; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; SKIN;

EID: 27644480270     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02910.x     Document Type: Article

References (37)

1. Greene BM, Taylor HR, Cupp EW et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985; 313:133-8.
2. Albiez EJ, Newland HS, White AT et al. Chemotherapy of onchocerciasis with high doses of diethylcarbamazine or a single dose of ivermectin: microfilaria levels and side effects. Trop Med Parasitol 1988; 39:19-24.
3. White AT, Newland HS, Taylor HR et al. Controlled trial and dosefinding study of ivermectin for treatment of onchocerciasis. J Infect Dis 1987; 156:463-70.
4. Soboslay PT, Newland HS, White AT et al. Ivermectin effect on microfilaria of Onchocerca volvulus after a single oral dose in humans. Trop Med Parasitol 1987; 38:8-10.
5. Richards FO Jr, Zea Flores R, Duke BO. Dynamics of microfilariae of Onchocerca volvulus over the first 72 hours after treatment with ivermectin. Trop Med Parasitol 1989; 40:299-303.
6. Darge K, Lucius R, Monson MH, Behrendsen J, Buttner DW. Immunohistological and electron microscopic studies of microfilariae in skin and lymph nodes from onchocerciasis patients after ivermectin treatment. Trop Med Parasitol 1991; 42:361-7.
7. Wildenburg G, Darge K, Knab J, Tischendorf FW, Bonow I, Buttner DW. Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop Med Parasitol 1994; 45:87-96.
8. Oliveira SHP, Lukacs NW. The role of chemokines and chemokine receptors in eosinophil activation during inflammatory allergic reactions. Braz J Med Biol Res 2003; 36:1455-63.
9. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250:91-104.
10. Cooper PJ, Guderian RH, Prakash D et al. RANTES in onchocerciasis: changes with ivermectin treatment. Clin Exp Immunol 1996; 106:462-7.
11. Cooper PJ, Beck LA, Espinel I et al. Eotaxin and RANTES expression by the dermal endothelium is associated with eosinophil infiltration after ivermectin treatment of onchocerciasis. Clin Immunol 2000; 95:51-61.
12. Gasim S, Elhassan AM, Kharazmi A, Khalil EA, Theander TG. The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 2000; 119:523-9.
13. Soboslay PT, Lüder CGK, Hoffmann WH et al. Ivermectin-facilitated immunity in onchocerciasis. Activation of parasite-specific Th1 type responses with subclinical Onchocerca volvulus infection. Clin Exp Immunol 1994; 96:238-44.
14. Grogan JL, Kremsner PG, Deelder AM, Yazdanbaksh M. Antigen-specific proliferation and interferon-gamma and interleukin-5 production are down-regulated during Schistosoma haematobium infection. J Infect Dis 1998; 177:1433-7.
15. Mutapi F, Ndhlovu PD, Hagan P et al. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis 1998; 178:289-93.
16. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-34.
17. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4:313-8.
18. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002; 16:1-4.
19. Schrum S, Probst P, Fleischer B, Zipfel PF. Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol 1996; 157:3598-604.
20. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, Leung DY. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 2003; 112:1195-202.
21. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 2004; 35:43-51.
22. Katoh S, Fukushima K, Matsumoto N et al. Accumulation of CCR4-expressing CD4+ T cells and high concentration of its ligands (TARC and MDC) in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy 2003; 58:518-23.
23. Matsumoto N, Mukae H, Nakamura-Uchiyama F et al. Elevated levels of thymus and activation-regulated chemokine (TARC) in pleural effusion samples from patients infested with Paragonimus westermani. Clin Exp Immunol 2002; 130:314-8.
24. Furukawa H, Takahashi M, Nakamura K, Kaneko F. Effect of an antiallergic drug (olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. J Dermatol Sci 2004; 36:165-72.
25. Jakubzick C, Wen H, Matsukawa A, Keller M, Kunkel SL, Hogaboam CM. Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am J Pathol 2004; 165:1211-21.
26. Leung TF, Tang NL, Li CY, Lam CW, Wong GW, Fok TF. Association between TARC C-431T and atopy and asthma in children. J Allergy Clin Immunol 2004; 114:199-202.
27. Hijnen D, De Bruin-Weller M, Oosting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113:334-40.
28. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci 2004; 34:201-8.
29. Bashir MEH, Andersen P, Fuss IJ, Shi HN, Nagler-Anderson C. An enteric helminth infection protects against an allergic response to dietary antigen. J Immunol 2002; 169:3284-92.
30. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002; 296:490-4.
31. Flohr C. Dirt, worms and atopic dermatitis. Br J Dermatol 2003; 148:871-7.
32. Wilson MS, Maizels RM. Regulation of allergy and autoimmunity in helminth infection. Clin Rev Allergy Immunol 2004; 26:35-50.
33. Homey B, Wang W, Soto H et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000; 164:3465-70.
34. Morales J, Homey B, Vicari AP et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999; 96:14470-5.
35. Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF. Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children. Clin Exp Dermatol 2004; 29:293-6.
36. Wong M, Silverman ED, Fish EN. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. J Rheumatol 1997; 24:1179-85.
37. Falcao PL, Correa-Oliveira R, Fraga LA et al. Plasma concentrations and role of macrophage inflammatory protein-1alpha during chronic Schistosoma mansoni infection in humans. J Infect Dis 2002; 186:1696-700.